Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Intravesical therapy in non-muscle-invasive bladder cancer
Der Urologe, 10/05/09
Simon J et al. – Intravesical treatment with various agents is an accepted standard for treating patients with non–muscle–invasive bladder cancer; all guidelines recommend its use. Depending on the agent and the instillation schedule, a reduction in recurrence and a decrease in the progression rate can be achieved. There is a great body of evidence that the effectiveness of intravesical chemotherapy can be increased by simple measures. Reduction of BCG side effects without compromising the oncological outcome is possible.
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09
Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients
Annals of Oncology, 11/10/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
What comes after docetaxel
Der Urologe, 11/18/09
Article Search
Sponsor


See Latest Articles


